|
1 Indications And Usage Juluca Is Indicated As A Complete Regimen For The Treatment Of Human Immunodeficiency Virus Type 1 (Hiv-1) Infection In Adults To Replace The Current Antiretroviral Regimen In Those Who Are Virologically Suppressed (Hiv-1 Rna Less Than 50 Copies Per Ml) On A Stable Antiretroviral Regimen For At Least 6 Months With No History Of Treatment Failure And No Known Substitutions Associated With Resistance To The Individual Components Of Juluca. Juluca, A Two-Drug Combination Of Dolutegravir, A Human Immunodeficiency Virus Type 1 (Hiv-1) Integrase Strand Transfer Inhibitor (Insti), And Rilpivirine, An Hiv-1 Non-Nucleoside Reverse Transcriptase Inhibitor (Nnrti), Is Indicated As A Complete Regimen For The Treatment Of Hiv-1 Infection In Adults To Replace The Current Antiretroviral Regimen In Those Who Are Virologically Suppressed (Hiv-1 Rna Less Than 50 Copies Per Ml) On A Stable Antiretroviral Regimen For At Least 6 Months With No History Of Treatment Failure And No Known Substitutions Associated With Resistance To The Individual Components Of Juluca. ( 1 )
|